Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists

Michael R. Braden, Jason C. Parrish, John C. Naylor and David E. Nichols
Molecular Pharmacology December 2006, 70 (6) 1956-1964; DOI: https://doi.org/10.1124/mol.106.028720
Michael R. Braden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason C. Parrish
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John C. Naylor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David E. Nichols
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Experiments were conducted to examine the molecular basis for the high affinity and potency of a new class of 5-HT2A receptor agonists, N-benzyl phenethylamines. Competition binding assays at several serotonin receptors confirmed that an N-arylmethyl substitution was necessary for affinity increases up to 300-fold over simple N-alkyl homologs, as well as enhanced selectivity for 5-HT2A versus 5-HT2C and 5-HT1A receptors. PI hydrolysis functional assays confirmed that these N-benzyl phenethylamines are potent and highly efficacious agonists at the rat 5-HT2A receptor. Virtual docking of these compounds into a human 5-HT2A receptor homology model indicated that the N-benzyl moiety might be interacting with Phe339(6.51), whereas the phenethylamine portion was likely to be interacting with Phe340(6.52). Experiments in h5-HT2A receptors with Phe339(6.51)L and Phe340(6.52)L mutations seem to support this hypothesis. Dramatic detrimental effects on affinity, potency, and intrinsic activity were observed with the Phe339(6.51)L mutation for all N-benzyl analogs, whereas most N-unsubstituted phenethylamines and traditional agonists were only weakly affected, if at all. Consistent with other published studies, the Phe340(6.52)L mutation detrimentally affected affinity, potency, and intrinsic activity of nearly all compounds tested, although a strong change in intrinsic activity was not seen with most N-aryl analogs. These data further validate the topology of our h5-HT2A receptor homology model. It is noteworthy that this study is the first to identify a hitherto unrecognized role for residue 6.51 in agonist activation of a serotonin G protein-coupled receptor (GPCR), whereas most previous reports have suggested a varied and sometimes contradictory role in homologous GPCRs.

Footnotes

  • This research was supported by National Institutes of Health grant DA02189 from the National Institute on Drug Abuse, and a grant from the Heffter Research Institute. The work was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Number C06-14499 from the National Center for Research Resources of the National Institutes of Health.

  • ABBREVIATIONS: LSD, d-lysergic acid diethylamide; 5-HT, 5-hydroxytryptamine, serotonin; CHO, Chinese hamster ovary; HEK, human embryonic kidney; psilocin, 4-hydroxy-N,N-dimethyltryptamine; 5-MeO-DMT, 5-methoxy-N,N-dimethyltryptamine; mescaline, 3,4,5-trimethoxyphenethylamine; DOI, 4-iodo-2,5-dimethoxyphenylisopropylamine; DOI-NBOMe, N-(2-methoxybenzyl)-4-iodo-2,5-dimethoxyphenylisopropylamine; 25H, 2,5-dimethoxyphenethylamine; 25H-NMe, N-methyl-2,5-dimethoxyphenethylamine; 25H-NPr, N-propyl-2,5-dimethoxyphenethylamine; 25H-NB, N-benzyl-2,5-dimethoxyphenethylamine; 25H-NBOMe, N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine; 25H-NBOH, N-(2-hydroxybenzyl)-2,5-dimethoxyphenethylamine; 24, 2,4-dimethoxyphenethylamine; 24-NB, N-benzyl-2,4-dimethoxyphenethylamine; 24-NBOMe, N-(2-methoxybenzyl)-2,4-dimethoxyphenethylamine; 24-NBOH, N-(2-hydroxybenzyl)-2,4-dimethoxyphenethylamine; 25I, 4-iodo-2,5-dimethoxyphenethylamine; 25I-NB, N-benzyl-4-iodo-2,5-dimethoxyphenethylamine; 25I-NNap, N-methylnapthyl-4-iodo-2,5-dimethoxyphenethylamine; 25I-NBOMe, N-(2-methoxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine; 25I-NBOH, N-(2-hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine; 25I-NBF, N-(2-fluorobenzyl)-4-iodo-2,5-dimethoxyphenethylamine; 25I-NBMD, N-(2,3-methylenedioxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine; PI, phosphatidylinositide(s); TM, transmembrane.

  • ↵ Embedded Image The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.

    • Received July 10, 2006.
    • Accepted September 25, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 70 (6)
Molecular Pharmacology
Vol. 70, Issue 6
1 Dec 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists

Michael R. Braden, Jason C. Parrish, John C. Naylor and David E. Nichols
Molecular Pharmacology December 1, 2006, 70 (6) 1956-1964; DOI: https://doi.org/10.1124/mol.106.028720

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists

Michael R. Braden, Jason C. Parrish, John C. Naylor and David E. Nichols
Molecular Pharmacology December 1, 2006, 70 (6) 1956-1964; DOI: https://doi.org/10.1124/mol.106.028720
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • α-Conotoxin Binding Site on the GABAB Receptor
  • Upacicalcet binds to the amino acid binding site of CaSR
  • Characterization of GRD and LCCH3 from Human Louse
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics